Symposia: Aggressive Lymphomas: Clinical and Epidemiological
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, epidemiology, Lymphomas, non-Hodgkin lymphoma, Clinical Research, B Cell lymphoma, Diseases, real-world evidence, aggressive lymphoma, Lymphoid Malignancies
Type: Oral
Hematology Disease Topics & Pathways:
Research, epidemiology, Lymphomas, non-Hodgkin lymphoma, Clinical Research, B Cell lymphoma, Diseases, real-world evidence, aggressive lymphoma, Lymphoid Malignancies
Saturday, December 9, 2023: 4:00 PM-5:30 PM
Grand Hall C
(Manchester Grand Hyatt San Diego)
Moderators:
Mehdi Hamadani, MD, The Medical College of Wisconsin Inc
and
Jeremy S. Abramson, MD, Massachusetts General Hospital Cancer Center
Disclosures:
Hamadani: ADC therapeutics: Consultancy, Honoraria, Research Funding, Speakers Bureau; Abbvie: Consultancy; Omeros: Consultancy; CRISPR: Consultancy; Genmab: Consultancy; Bristol Myers Squibb: Consultancy; Caribou: Consultancy; AstraZeneca: Speakers Bureau; Kite, a Gilead Company: Consultancy, Speakers Bureau; BeiGene: Speakers Bureau; Gamida Cell: Consultancy; Incyte: Consultancy; Genmab: Consultancy; Kadmon: Consultancy; Legend Biotech: Consultancy; MorphoSys: Consultancy; Novartis: Consultancy; SeaGen: Consultancy; Astra Zeneca: Speakers Bureau; BeiGene: Speakers Bureau; Sanofi Genzyme: Speakers Bureau; Astellas: Research Funding; Spectrum Pharmaceuticals: Research Funding; Takeda: Research Funding; Genentech: Honoraria; Myeloid Therapeutics: Honoraria. Abramson: AbbVie: Consultancy; AstraZeneca: Consultancy, Honoraria; BeiGene: Consultancy; BMS: Consultancy, Honoraria, Research Funding; Caribou Biosciences: Consultancy; Cellectar Biosciences: Consultancy; Century Therapeutics: Consultancy; Epizyme: Consultancy; Genentech: Consultancy; Genmab: Consultancy; Incyte: Consultancy; Interius: Consultancy; Janssen: Consultancy, Honoraria; Kite Pharma: Consultancy; Kymera: Consultancy; Lilly: Consultancy; Merck: Research Funding; MorphoSys: Consultancy; Mustang Bio: Consultancy, Research Funding; Ono Pharma: Consultancy; Regeneron: Consultancy, Honoraria; Seagen Inc.: Research Funding; Takeda: Consultancy; Celgene: Consultancy; Novartis: Consultancy; EMD Serono: Consultancy; Alimera Sciences: Consultancy; Karyopharm Therapeutics: Consultancy; C4 Therapeutics: Consultancy; Bluebird Bio: Consultancy; AI Therapeutics: Research Funding.
This session provides retrospective data on outcomes of patients with relapsed/refractory large B-cell lymphoma treated in the modern era with immunochemotherapy, CAR T-cell, and novel agents.
4:00 PM
4:15 PM
4:30 PM
4:45 PM
5:00 PM
5:15 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH